On 11/14/23, Editas Medicine Inc (NASDAQ: EDIT) stock enjoyed a major increase of 11.4%, closing at $8.52. The stock has performed in line with the market over the last nine months and has risen 2.5% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, EDIT is expected to continue to be Value Creation neutral.
Editas Medicine has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Editas Medicine has a neutral Power Rating of 42 but a poor Appreciation Score of 16, with the Lowest Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment